New York State Common Retirement Fund Has $62,000 Position in XOMA Co. (NASDAQ:XOMA)

New York State Common Retirement Fund increased its stake in shares of XOMA Co. (NASDAQ:XOMA) by 51.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,362 shares of the biotechnology company’s stock after acquiring an additional 800 shares during the period. New York State Common Retirement Fund’s holdings in XOMA were worth $62,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. BNP Paribas Financial Markets raised its stake in XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 795 shares during the period. Geode Capital Management LLC grew its position in XOMA by 0.6% during the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after buying an additional 1,138 shares in the last quarter. Rhumbline Advisers grew its position in XOMA by 18.1% during the fourth quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock worth $291,000 after buying an additional 1,699 shares in the last quarter. State Street Corp boosted its holdings in shares of XOMA by 1.2% in the 3rd quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock valued at $3,783,000 after purchasing an additional 1,754 shares in the last quarter. Finally, Barclays PLC boosted its holdings in shares of XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares in the last quarter. Institutional investors own 95.92% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. HC Wainwright cut their price objective on XOMA from $123.00 to $104.00 and set a “buy” rating on the stock in a report on Monday, February 3rd. StockNews.com lowered XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th.

XOMA Price Performance

XOMA stock opened at $21.69 on Friday. The company has a market capitalization of $255.57 million, a P/E ratio of -6.23 and a beta of 0.90. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. XOMA Co. has a 52-week low of $20.87 and a 52-week high of $35.00. The business has a 50-day simple moving average of $25.61 and a two-hundred day simple moving average of $27.81.

Insider Buying and Selling at XOMA

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the company’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 7.20% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.